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Abstract Desmoplastic small round cell tumor (DSRCT) is a
malignant human cancer that is associated with a specific
t(11;22) chromosome translocation, where 265 amino acids from
the EWS amino-terminus are fused to the DNA binding domain
of the WT1 tumor suppressor gene. We have noticed the presence
of several SH3 interacting domains within the amino-terminus of
EWS and have assessed the potential of EWS/WT1 to interact
with such motifs. We find that EWS/WT1 can associate with the
SH3 domain of several proteins, including v-Src. Ectopic
expression of v-Src phosphorylates EWS/WT1 in vivo, as well
as enhances the transactivation ability of the EWS amino-
terminal domain. Structural alteration of the v-Src SH2 or SH3
domains produced mutants that could not interact with EWS/
WT1 nor augment the transcriptional properties of EWS. Taken
together, our results suggest the possibility that some transcrip-
tional properties of EWS/WT1 may be regulated by a
cytoplasmic signaling pathway.
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1. Introduction
Desmoplastic small round cell tumor (DSRCT) is an ag-
gressive neoplasm with a poor prognosis that a¡ects children
and young adults. This tumor is characterized by: (i) nests
and clusters of undi¡erentiated small round cells separated by
a prominent desmoplastic stroma, (ii) polyphenotypic di¡er-
entiation, and (iii) a reciprocal chromosomal translocation
t(11;22)(p13;q12), which fuses the amino-terminal domain
(NTD) of the EWS gene in-frame to three of the four car-
boxy-terminal zinc ¢ngers of the WT1 tumor suppressor gene
[1^3]. The EWS gene is involved in several tumor-related
chromosome translocations that produce fusions between
the EWS amino-terminal domain (NTD) and a carboxy-ter-
minal domain often consisting of a DNA binding domain
derived from one of a number of transcription factors [4,5].
The Wilms’ tumor suppressor gene, WT1, encodes a zinc ¢n-
ger transcription factor belonging to the EGR (early growth
response) family of Cys2^His2 zinc ¢nger proteins and is mu-
tated in 5^15% of sporadic WTs [6]. The pre-mRNA is alter-
natively spliced at two coding exons to produce four WT1
polypeptide isoforms containing four zinc ¢ngers [7]. The ¢rst
alternative splice event produces WT1 isoforms containing or
lacking 17 amino acids approximately midway within the cod-
ing region, whereas the second alternative splice site inserts
(+) or removes (3) three amino acids ( þ KTS), between zinc
¢ngers III and IV and alters the DNA binding speci¢city of
the protein [8].
EWS/WT1 is a chimeric protein that contains the NTD of
EWS and three of the four C-terminal zinc ¢ngers from WT1,
as well as retaining the second alternative splicing event be-
tween zinc ¢ngers III and IV [1,3]. The portion of EWS that
displaces the NTD of the WT1 tumor suppressor gene en-
codes a potent transcriptional activator [9]. This chimeric pro-
tein has been shown to up-regulate putative WT1 downstream
targets, such as PDGF-A [10], EGR-1 [11], and IGF-1R [12],
which are normally down-regulated by WT1 (reviewed in [6]).
In addition, the EWS/WT1 fusion protein plays an important
role in the development of DSRCT. Overexpression of EWS/
WT1(3KTS), but not EWS/WT1(+KTS), is oncogenic when
introduced into NIH3T3 cells [13].
Transformation of cells by non-nuclear oncoproteins leads
to deregulated transcription in the nucleus ^ a decisive event
in cell transformation resulting in altered transcription of cer-
tain genes (reviewed in [14]). One of the possible themes is
that di¡erent proto-oncogene products function as compo-
nents of a network that transduces signals from the exterior
of the cell to transcription factors in the nucleus [14]. For
example, many of the biological activities of v-Src (an onco-
gene of the Rous sarcoma virus and a member of non-recep-
tor tyrosine kinases) involve changes in gene transcription and
this protein is capable of activating a variety of transcription
factors (reviewed in [15,16]). It has been reported that v-Src
mediated transcriptional activation involves multiple tran-
scription control elements, including NF-UB, ATF/CRE,
AP-1, CArG, and SIE sites [17^21].
For example, Bruton’s tyrosine kinase (Btk), a member of
the Tec family of non-nuclear receptor tyrosine kinases con-
taining SH1, SH2, and SH3 domains but lacking the typical
myristylation site and negative regulatory tyrosine present in
Src family kinases [22], has been demonstrated to enhance
TFII-I mediated transcriptional activation [23]. Interestingly,
Btk associates with TFII-I and phosphorylates TFII-I on ty-
rosine residues in vivo. Transcription activation of the c-fos
promoter by TFII-I in serum stimulated NIH3T3 cells re-
quires an intact Ras signalling pathway [24]. Taken together,
these data suggest that certain transcription factors, including
TFII-I, link signal transduction to transcription events in the
cell.
In this study, we report that v-Src can associate with, and
phosphorylate, EWS/WT1. We also ¢nd that transcriptional
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activation by the EWS-NTD is stimulated by v-Src. These
data suggest that the transcriptional activation properties of
EWS(NTD) can be in£uenced by a cytoplasmic signaling
pathway.
2. Materials and methods
2.1. Materials and general methods
Restriction endonucleases and DNA modifying enzymes were pur-
chased from New England Biolabs (Beverly, MA, USA).
[35S]deoxyadenosine 5P (K-thio) triphosphate (1000^1500 Ci/mmol),
[35S]methionine (s 1000 Ci/mmol), and D-threo-[dichloroacetyl-1-
14C]chloramphenicol (54.0 Ci/mmol) were obtained from New Eng-
land Nuclear. Preparation of plasmid DNA, restriction enzyme diges-
tion, agarose gel electrophoresis of DNA, DNA ligation, and bacterial
transformations were carried out using standard methods ([25] and
references therein). Subclones of DNA PCR ampli¢cations were al-
ways sequenced to ensure the absence of unwanted secondary muta-
tions.
2.2. Plasmid constructions
Descriptions of EWS/WT1(3KTS), 5UGal4WE1BWCAT, GAL4,
GAL4-EWS(NTD), pcDNA3/GST, and pcDNA3/GST-EWS/
WT1(3KTS) have been previously presented [9,26]. To generate
pcDNA3/v-Src, the BamHI fragment of MMTV/v-Src (obtained
from Dr. John Bell, Ottawa, Canada) was subcloned into the BamHI
site of pcDNA3. For generating GST/Unique v-Src, the unique
domain of v-Src was ampli¢ed by the PCR using primer 5P-Src/Uni
(5P-GATCGAATTCATGGGGAGTAGCAAGAGC-3P) and primer
3P-Src/Uni (5P-GATCCTCGAGGGCACGCTGCGGCGACGT-3P),
digested with EcoRI and XhoI, and cloned into the same sites of
pGEX(4T-1). For GST/SH3 v-Src, the SH3 domain of v-Src was
generated by the PCR using primer 5P-Src/SH3 (5P-GATCGAA-
TTCGGGGCACTGGCTGGCGGC-3P) and primer 3P-Src/SH3 (5P-
GATCCTCGAGGGGGTTTTCGGGGTTGAG-3P), digested with
EcoRI and XhoI, and cloned into the same sites of pGEX(4T-1). To
generate GST/SH2 v-Src, the SH2 domain of v-Src was ampli¢ed by
the PCR using primer 5P-Src/SH2 (5P-GATCGAATTCTGGTAC-
TTTGGGAAGATC-3P) and primer 3P-Src/SH2 (5P-GATCCTCGAG-
GGTCTGGGGCTTGGACGT-3P), digested with EcoRI and XhoI,
and cloned into the same sites of pGEX(4T-1). To generate GST/Ki-
nase v-Src, the kinase domain of v-Src was ampli¢ed by the PCR
using primer 5P-Src/Kinase (5P-GATCGAATTCCAGGGACTCGCC-
AAGGAC-3P) and primer 3P-Src/Kinase (5P-GATCCTCGAGC-
TACTCAGCGACCTCCAA-3P), digested with EcoRI and XhoI,
and cloned into the same sites of pGEX(4T-1). The restriction enzyme
sites for EcoRI (5P-GAATTC-3P) and XhoI (5P-CTCGAG-3P) in the
PCR primers are indicated by underlines.
Mammalian expression plasmids pcDNA3/v-Src vSH3WSH2, v-Src
vKinase, and v-Src R295 were constructed by the PCR. (A) pcDNA3/
v-Src vSH3WSH2. The unique domain of v-Src was generated by the
PCR using primer 5P-Src-1 (5P-GATCAAGCTTATGGGGAGTAG-
CAAGAGC-3P) and 3P-Src-76 (5P-GGCACGCTGCGGCGACGT-3P)
and the kinase domain of v-Src was generated by PCR using the
primer 5P-Src-253 (5P-CAGGGACTCGCCAAGGAC-3P) and 3P-Src-
4 (5P-GATCTCTAGACTACTCAGCGACCTCCAA-3P). These PCR
products were kinased and ligated together, digested with HindIII and
XbaI, and cloned into the same sites of pcDNA3. (B) pcDNA3/v-Src
vKinase. The v-Src vKinase domain (aa 1^258) was generated by the
PCR using primers 5P-Src-1 and 3P-Src/ter-258 (5P-CTAGTCCTT-
GGCGAGTCCCTG-3P), digested with HindIII after kinasing with
T4 polynucleotide kinase, and subcloned into the HindIII and EcoRV
sites of pcDNA3. (C) pcDNA3/v-Src R293. PCRs were performed
with primers 5P-Src-1 and 3P-Src-2 (5P-GGTGCCGGGCTTCAGA-
GTCCTTATGGCCACTCTGGTGGT-3P) for the N-terminal part
and 5P-Src-3 (5P-ATGTCCCCGGAGGCCTTC-3P) and 3P-Src-4 for
the C-terminal part of v-Src, respectively. These PCR products were
ligated, digested with HindIII and XbaI, and cloned into the same
sites of pcDNA3. The HindIII (AAGCTT) and XbaI (TCTAGA) sites
are indicated by underlines.
Description of plasmids GST-EWS/WT1 and GST-EWS/
WT1(NTD), used for GST pull-down assays, have been described
previously [26]. (A) GST-EWS/WT1(1^245). The BamHI fragment
of pGEX(RC)-EWS/WT1 was subcloned into the BamHI site of
pGEX(RC). (B) GST-EWS/WT1(1^163). Plasmid pGEX(RC)-EWS/
WT1 was digested with AvrII and HindIII, blunt end repaired with
klenow, and re-ligated. (C) GST-EWS/WT1(1^109). Plasmid pGAL4/
EWS(1^109) [9] was cleaved with EcoRI and NotI and cloned into the
same sites of pGEX(4T-1). (D) GST-EWS/WT1(1^35). Plasmid
pGEX(RC)-EWS/WT1 was cleaved with NdeI and HindIII, blunt
end repaired with klenow and re-ligated. (E) GST-EWS/WT1(70^
200). The EWS/WT1(70^200) fragment was generated by the PCR
using primers 5P-aa70 (5P-GATCGAATTCTATGGACAGCCTCC-
CACT-3P) and primer 3P-aa200 (5P-GATCCTCGAGCGGCTGTG-
TAGAGGAATA-3P), digested with EcoRI and XhoI, and cloned
into the same sites of pGEX(4T-1). (F) GST-EWS/WT1(192^265).
The EWS/WT1(192^265) PCR product was produced by the PCR
using primers 5P-aa192 (5P-GATCGAATTCCCTACCAGCTATTCC-
TCT-3P) and 3P-aa265 (5P-GATCCTCGAGACTCTGCTGCCCGT-
AGCT-3P), cleaved with EcoRI and XhoI and ligated into the same
sites of pGEX(4T-1). (G) GST-EWS/WT1(245^362). Plasmid
pcDNA3-EWS/WT1(3KTS) was digested with BamHI and XhoI
and the excised fragment was cloned into the same sites of
pGEX(RC). (H) GST-EWS/WT1(70^163). The PCR product from
amino acids 70^163 of EWS/WT1 was produced by the PCR using
primers 5P-aa70 and 3P-aa163 (5P-GATCCTCGAGTAGGCT-
GGGCTGGTTGTA-3P), cleaved with EcoRI and XhoI, and cloned
into the same sites of pGEX(4T-1). (I) GST-EWS/WT1(140^200). The
EcoRI and XhoI cleaved EWS/WT1(140^200) was produced by the
PCR using primer 5P-aa140 (5P-GATCGAATTCCAGGATGGAAA-
CAAGCCC-3P) and primer 3P-aa200, digested with EcoRI and XhoI
and ligated into the same sites of pGEX(4T-1).
2.3. In vitro transcription and translation
In vitro transcriptions and translations were performed as previ-
ously described [9]. Brie£y, pcDNA3:EWS/WT1 or pcDNA3/v-Src
were linearized with SmaI or DraI, respectively, and in vitro tran-
scriptions performed with T7 RNA polymerase. In vitro translations
were performed in the presence of [35S]methionine in rabbit reticulo-
cyte lysates, essentially as described by the manufacturer’s instructions
(Promega). For analysis of integrity, all in vitro translation products
were electrophoresed on 10% SDS^PAGE.
2.4. GST pull-down assays
All GST fusion proteins were puri¢ed according to the manufac-
turer’s recommendations with slight modi¢cations [9]. Brie£y, bacte-
rial extracts containing GST or GST fusion proteins were incubated
with a 50% slurry of glutathione-agarose beads (Pharmacia) in cou-
pling bu¡er [50 mM Tris^HCl (pH 8.0), 1% NP-40, 2 mM EDTA,
150 mM NaCl, 2 mM of PMSF (phenylmethylsulfonyl £uoride),
10 Wg/ml aprotinin, 10 Wg/ml leupeptin, and 10 Wg/ml antipain] with
rocking. GST or GST fusion proteins bound to beads were then
collected by brief centrifugation and washed four times in wash bu¡er
(coupling bu¡er plus 10% glycerol). In vitro synthesized [35S]meth-
ionine labeled v-Src was incubated with immobilized GST or GST-
EWS/WT1 fusion proteins in binding bu¡er (wash bu¡er plus 1 mM
DTT) for 1 h at 4‡C. The beads were collected by centrifugation and
washed four times with binding bu¡er. Bound proteins were eluted
from the beads by boiling in 1USDS loading bu¡er (62.5 mM Tris^
HCl (pH 6.9), 10% glycerol, 2% SDS, 5% L-mercaptoethanol) and
were separated by electrophoresis. Protein gels were treated with
EN3HANCE (NEN Research Products) before drying and exposed
to Kodak X-Omat ¢lm.
2.5. Cell culture, transfection, a⁄nity precipitation, immunoblotting,
and CAT assays
C33A or 293T cell lines were maintained in minimum essential
medium (K-MEM) or Dulbecco’s modi¢ed Eagle’s medium (D-
MEM) supplemented with 10% heat inactivated fetal calf serum (Gib-
co-BRL), penicillin, and streptomycin. Using calcium phosphate pre-
cipitation, cells were co-transfected with 10 Wg of pcDNA3/v-Src to-
gether with either 10 Wg of pcDNA3:GST or pcDNA3:GST-EWS/
WT1. After 48 h, cells were harvested and lysed in a bu¡er containing
50 mM Tris^HCl (pH 8.0), 1% NP-40, 2 mM EDTA, 150 mM NaCl,
1 mM DTT, 2 mM of PMSF (phenylmethylsulfonyl £uoride), 10 Wg/
ml aprotinin, 10 Wg/ml leupeptin, and 10 Wg/ml antipain for 30 min on
ice. Lysates were clari¢ed by centrifugation at 16 000Ug for 15 min at
4‡C and incubated with glutathione beads for 1 h. Beads were col-
lected by brief centrifugation and washed with the same bu¡er four
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times. The a⁄nity-precipitated proteins were eluted in the same man-
ner as described above, separated by electrophoresis through a 10%
polyacrylamide gel, and transferred onto an Immobilon-P polyvinyli-
done di£uoride membrane (Millipore). This ¢lter was blocked with
5% non-fat in TBS-T (20 mM Tris^HCl (pH 7.5), 150 mM NaCl,
0.1% Tween 20) for 1 h at room temperature, then a⁄nity-puri¢ed
monoclonal anti-Src antibody (LA074, Quality Biotech., National
Cancer Institute) and HRP (horseradish peroxidase)-conjugated goat
anti-mouse antibody (Santa Cruz Biotechnology, Inc.) were used as
primary and secondary antibody, respectively. The blot was incubated
and visualized by ECL (DuPont NEN) according to manufacturer’s
instructions.
For CAT assays, C33A cell lines were transfected with the indicated
amounts of DNAs. Individual DNA precipitates were adjusted to
contain equal amounts of total DNA by the addition of the empty
expression vector, pcDNA3. To normalize for transfection e⁄ciency,
cells were co-transfected with 2 Wg of pRSV/L-gal. At 48 h after trans-
fection, cells were harvested and assayed for L-galactosidase and CAT
activity [27]. Following thin layer chromatography analysis, regions
containing acetylated [14C]chloramphenicol, as well as unacetylated
[14C]chloramphenicol, were quantitated by direct analysis on a Phos-
phoImager (Fujix BAS 2000).
For anti-phosphotyrosine blots, (His)6-tagged EWS/WT1(3KTS)
proteins were puri¢ed according to the manufacturer’s recommenda-
tions (QIAGEN) with slight modi¢cations. Brie£y, total cell extracts
containing (His)6-tagged proteins were prepared by sonication, centri-
fuged, and the supernatant collected by centrifugation. The superna-
tant was incubated with an Ni-NTA agarose resin (QIAGEN) in
binding bu¡er (8 M urea, 0.1 M sodium phosphate, 10 mM Tris^
HCl (pH 8.0)) and washed with wash bu¡er (8 M urea, 0.1 M sodium
phosphate, 10 mM Tris^HCl (pH 6.3)) four times. The bound protein
was eluted with elution bu¡er (wash bu¡er supplemented with 0.1 M
EDTA). The a⁄nity-puri¢ed EWS/WT1(3KTS) proteins were sepa-
rated by electrophoresis through a 10% polyacrylamide gel, and trans-
ferred onto an Immobilon-P polyvinylidone di£uoride membrane
(Millipore). To quantitate levels of tyrosine phosphorylation, 5% bo-
vine serum albumin (Amresco) in TBS-T was used for pre-blocking
and the anti-phosphotyrosine antibody (4G10, UBI) was used for
probing. To quantitate the amounts of EWS/WT1 protein, ¢lters
were stripped with stripping bu¡er (62.5 mM Tris^HCl (pH 6.8),
2% SDS, 97.9 mM L-mercaptoethanol) for 30 min at 50‡C and re-
probed with an antibody that recognizes the C-terminus of the WT1
zinc ¢ngers (C-19 (Santa Cruz Biotechnology)). The blot was incu-
bated and visualized by ECL according to manufacturer’s instructions
(DuPont NEN).
3. Results
3.1. EWS/WT1 interacts with SH2 and SH3 domain containing
proteins
We have previously documented that EWS/WT1 is a sub-
strate for phosphorylation by c-Abl, and that this event in-
hibits DNA binding and self-association by EWS/WT1 [26].
Since proline-rich domains, of the type found in the EWS-
NTD (see below) are known to interact with SH3 domains,
we assessed whether EWS/WT1 could interact with other SH3
domain containing proteins.
In this experiment, [35S]Met labeled EWS/WT1 protein was
prepared by in vitro translation and GST pull-down assays
were performed with GST fusion proteins containing the SH3
regions of various protein tyrosine kinases and adapter pro-
teins. The EWS/WT1 protein was retained by fusion proteins
containing the c-Abl and v-Src SH3 domains (Fig. 1A). A
small amount of binding was also noted to the SH3 domain
of Crk(N) (Fig. 1A). However in this assay, the EWS/WT1
protein did not bind to the SH3 domains of Spectrin, Ras-
GAP, PLC-Q, Grb2(N), Grb2(C), and p85K (the regulatory
subunit of P13 kinase) (Fig. 1A). Thus, EWS/WT1 binds dif-
ferentially to the SH3 domains tested and provides a molec-
ular selectivity that can distinguish among SH3 domains. The
lack of reactivity of several di¡erent SH3 domains with EWS/
WT1 suggests that the EWS/WT1 interaction is speci¢c and
that di¡erent types of SH3 domains are not equivalent.
EWS/WT1 is also expected to be an SH2 domain interact-
ing protein, since it is tyrosine phosphorylated [26] and con-
tains potential interacting motifs for SH2 domains. We thus
performed a series of GST pull-down assays to assess whether
EWS/WT1 was capable of interacting with these. As shown in
Fig. 1B, EWS/WT1 was able to bind to the SH2 domains of
Grb2, Fyn, GAP(N+C), and v-Src. However, EWS/WT1 did
not show any binding to the c-Abl, Shc, CSK, Nck, and PLC-
Q SH2 domains. These results indicate that EWS/WT1 can
bind to SH2 domains, in addition to SH3 domains. For the
Fig. 1. EWS/WT1 can bind to SH3 and SH2 domains. A: Di¡eren-
tial binding of EWS/WT1 to SH3 domains. [35S]Met labeled EWS/
WT1 was incubated with GST fusion proteins containing the SH3
regions of c-Abl, Spectrin, v-Src, RasGAP, PLC-Q, Grb2(N),
Grb2(C), or p85K. An aliquot of the input (20%) and the pellet
from the various GST-SH3 pull-downs were analyzed on a 10%
SDS^PAGE and the bound EWS/WT1 protein was visualized by
£uorography. The GST-SH3 domains from various proteins are in-
dicated at the top of each lane. The positions of migration of the
molecular weight markers are indicated to the left, and EWS/WT1
is indicated by an arrow to the right. B: Binding analysis of EWS/
WT1 to SH2 domains. The SH2 domains indicated above each lane
were expressed as GST fusion proteins and utilized in GST pull-
down assays with [35S]Met labeled EWS/WT1 protein. An aliquot
of input (10%), as well as pellets from the various GST-SH2 pull-
downs were analyzed on a 10% SDS^PAGE and visualized by £uo-
rography. The positions of migration of molecular weight markers
and of EWS/WT1 are indicated.
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purpose of the current study, we focused on better de¢ning
and characterizing the interaction between EWS/WT1 and
v-Src.
3.2. The proline-rich motif of EWS/WT1 is involved in
v-Src interaction
To de¢ne the minimal region within EWS/WT1 required to
bind to v-Src, a series of deletion mutants were generated. The
proline-rich domain of EWS/WT1 contains six P-X-X-P mo-
tifs (P1 (80PTAP83), P2 (122PAYP125), P3 (136PTRP139), P4
(173PQVP176), P5 (180PMQP183), and P6 (188PSYP191)) which
could act as SH3 domain interacting sites. To determine
which domain(s) within EWS/WT1 might mediate v-Src inter-
action, in vitro binding experiments were performed with a
series of EWS/WT1 deletion mutants (Fig. 2). In this experi-
ment, GST-EWS/WT1 fusion proteins were used in a⁄nity
precipitation experiments utilizing radiolabeled v-Src pro-
duced from in vitro translations. v-Src bound to GST-EWS/
WT1, GST-EWS/WT1(NTD), GST-EWS/WT1(1^245), and
GST-EWS/WT1(1^163), but failed to bind to: (i) C-terminal
deletion mutants GST-EWS/WT1(1^109) and GST-EWS/
WT1(1^35), (ii) the internal domain mutant (GST-EWS/
WT1(192^265)), and (iii) the DNA binding domain mutant
(GST-EWS/WT1(245^265)) (Fig. 2). Fusion protein GST-
EWS/WT1(70^200), which contains all six P-X-X-P motifs
(amino acids 80^191) bound to in vitro translated v-Src, as
did GST-EWS/WT1(70^163), which contains the ¢rst three P-
X-X-P motifs (P1^P3) (Fig. 2). GST-EWS/WT1(140^200),
containing P-X-X-P motifs P4^P6, lost the ability to interact
with v-Src, indicating that amino acids 70^163 contain the
responsible domain(s) for v-Src interaction (Fig. 2).
3.3. Only the SH3 and SH2 domains of v-Src interact with
EWS/WT1
Although we have shown that EWS/WT1 can interact with
both SH2 and SH3 domains of v-Src (Fig. 1), these results do
not preclude additional sites within v-Src which could interact
with EWS/WT1. To address this issue, a series of in vitro GST
pull-down assays were performed with GST fusions of v-Src
(Fig. 3A). The v-Src functional regions, such as the unique
domain (aa 1^76), the SH3 domain (aa 77^168), the SH2
domain (aa 148^252), and the kinase domain (aa 253^526),
were generated by the PCR, individually expressed as GST
fusion proteins in Escherichia coli, and coupled to gluta-
thione-Sepharose beads. Following incubation with [35S]Met
labeled EWS/WT1 protein and extensive washing, only GST
fusions containing the SH3 or SH2 domains were able to
speci¢cally retain EWS/WT1 (Fig. 3B). EWS/WT1 did not
interact with the amino-terminal unique domain or the car-
boxy-terminal kinase domain (Fig. 3B). These results suggest
that the association of EWS/WT1 with v-Src can be mediated
independently by the SH2 or SH3 domains.
Fig. 2. Mapping of the v-Src interacting domain of EWS/WT1. The EWS/WT1 cDNA fragments fused in-frame to the GST gene in pGEX
vector are schematically shown. Proteins from E. coli that expressed recombinant pGEX vectors encoding the various GST-EWS/WT1 fragment
fusion proteins were incubated with [35S]Met labeled in vitro translated v-Src protein. Following washing, the bound proteins were eluted with
SDS loading bu¡er and proteins were analyzed by 10% SDS^PAGE. The + or 3 symbols to the left refer to the ability (or inability) to bind
to v-Src. The six putative EWS/WT1 SH3 binding motifs (P-X-X-P) are indicated as P1^P6.
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3.4. Association between EWS/WT1 and v-Src in vitro and in
vivo
To determine whether the interaction between EWS/WT1
and v-Src occurred in vivo, we performed coa⁄nity precipita-
tions following transfection of 293T cells with expression vec-
tors driving the synthesis of both proteins. Plasmid
pcDNA3:GST-EWS/WT1 (a mammalian expression vector
containing EWS/WT1 fused to GST) or pcDNA3:GST (a
mammalian expression vector containing the GST domain)
were co-transfected with pcDNA3/v-Src into 293T cells. Cells
were lysed 48 h after transfection, GST or GST-EWS/WT1
fusions were a⁄nity-precipitated with glutathione beads, and
subsequently immunoblottings performed on the eluents using
an anti-Src antibody (LA074, Quality Biotech., National Can-
cer Institute) to detect the presence of v-Src (Fig. 4A). Con-
sistent with in vitro binding assays, v-Src is speci¢cally copre-
cipitated with GST-EWS/WT1, but not with GST alone (Fig.
4A). These results suggest that EWS/WT1 and v-Src can as-
sociate in vivo.
To eliminate the possibility that an uncharacterized eukary-
otic adapter molecule was mediating the interaction between
EWS/WT1 and v-Src, we performed the following experiment.
Recombinant (His)6-tagged EWS/WT1 protein was puri¢ed
from E. coli and used in pull-down assays with GST/SH3 v-
Src which had also been produced in E. coli. As shown in Fig.
4B, both bacterially produced proteins could interact, suggest-
ing that the v-Src-EWS/WT1 interaction does not require an
adapter protein.
3.5. EWS/WT1 is a substrate of v-Src in vivo
To determine whether v-Src could phosphorylate EWS/
WT1, we performed in vitro kinase assays (Fig. 5). Myelin
basic protein (MBP) was used as an internal control to mon-
itor the v-Src kinase activity in each incubation. In vitro in-
cubation of recombinant GST-EWS/WT1 with commercially
available v-Src protein kinase, resulted in the phosphorylation
of GST-EWS/WT1 (Fig. 5A). No corresponding radiolabeled
product could be detected in v-Src or GST control lanes,
respectively. These results demonstrate that v-Src tyrosine ki-
nase can directly phosphorylate GST-EWS/WT1. The obser-
vation that GST alone is not a substrate establishes that phos-
phorylation occurs within the EWS/WT1 part of the fusion
protein. The amino acid acceptor of EWS/WT1 was estab-
lished by phospho-amino acid analysis. Only phosphotyrosine
(pY) was detected in EWS/WT1 (Fig. 5B). To determine
whether EWS/WT1 is a substrate for v-Src in vivo, a plasmid
encoding (His)6-tagged EWS/WT1 was transfected into C33A
cells with v-Src cDNA or control vector, respectively. Forty-
eight hours after transfection, cells were lysed under denatur-
ing conditions and (His)6-EWS/WT1 proteins were a⁄nity-
precipitated with Ni2-NTA resin. A⁄nity-puri¢ed EWS/
WT1 proteins were fractionated by SDS^PAGE, transferred
to PVDF membrane, and immunoblotted with an anti-EWS/
WT1 antibody (C-19) to quantitate the amount of proteins in
each sample (Fig. 5C, top panel). To detect tyrosine phos-
phorylation, the anti-phosphotyrosine antibody, 4G10, was
used as a probe (Fig. 5C, bottom panel). Signi¢cant amounts
of tyrosine phosphorylation were detected on EWS/WT1 pro-
tein in cells co-transfected with v-Src (Fig. 5C, bottom panel),
but not in cells co-transfected with vector alone. These data
suggest that EWS/WT1 is a substrate for v-Src in vivo
although further experiments would be required to demon-
strate whether the EWS/WT1 phosphorylated sites obtained
in vivo are the same as those obtained in vitro.
Fig. 3. The SH3 and SH2 domains of v-Src mediate EWS/WT1
binding. A: Schematic representation of the GST fusion v-Src deriv-
atives used in this study. Constructs GST/Unique, GST/SH3, GST/
SH2, and GST/Kinase represent the GST domain fused to the v-Src
unique, SH3, SH2, and kinase domains, respectively. GST fusion
proteins from induced lysates of E. coli expressing recombinant
pGEX vectors encoding the various functional domains of v-Src
protein were incubated with [35S]Met labeled EWS/WT1 protein.
Following washing, the bound proteins were eluted and analyzed by
SDS^PAGE. The + or 3 symbols to the left refer to the ability (or
inability) of the GST fusions to retain EWS/WT1. B: Binding of
EWS/WT1 to the v-Src SH2 and SH3 domains. Following GST
pull-down assays, eluted fractions were analyzed by SDS^PAGE.
The positions of molecular weight markers are indicated to the left
and the position of EWS/WT1 is indicated on the right.
Fig. 4. Interaction between EWS/WT1 and v-Src in vivo. A: Co-af-
¢nity precipitation of v-Src with GST-EWS/WT1. Plasmid
pcDNA3:v-Src was co-transfected with pcDNA3:GST (lane 1) or
pcDNA3:GST-EWS/WT1 constructs (lane 2). Following lysis of the
transfected cells 48 h after transfection, a⁄nity precipitations were
performed with glutathione-Sepharose 4B beads. The a⁄nity precip-
itates were analyzed for the presence or absence of v-Src protein by
Western blotting utilizing an anti-Src antibody (LA074). The posi-
tions of the molecular weight markers are indicated to the left and
the position of migration of v-Src is indicated by an arrow to the
right. B: Direct interaction between EWS/WT1 and the SH3 do-
main of v-Src. Bacterially produced (His)6-tagged EWS/WT1 protein
was incubated with GST alone or GST-SH3, and GST pull-downs
performed as described in Section 2. An aliquot of the input (20%)
and of the pellets from the pull-down assays was fractionated on a
10% SDS^PAGE, blotted onto PVDF membrane, and the bound
EWS/WT1 protein was detected with an K-WT1 zinc ¢nger antibody
(C19).
FEBS 23718 25-5-00
J. Kim et al./FEBS Letters 474 (2000) 121^128 125
3.6. v-Src stimulates transactivation by the EWS(NTD)
A number of studies have shown that v-Src can indirectly
activate [28,29] or repress [30,31] the expression of genes en-
coding a wide variety of cellular proteins. To test whether co-
expression of v-Src could in£uence EWS(NTD) mediated
transcriptional activation, cells were co-transfected with (i) a
v-Src expression plasmid, (ii) an expression vector containing
a GAL4 DNA binding domain fused to the EWS-NTD and,
(iii) a reporter plasmid containing the E1B minimal promoter
harboring ¢ve GAL4 DNA binding sites. Consistent with pre-
viously reported data [9], introduction of GAL4-EWS(NTD)
in C33A cells signi¢cantly activated transcription (V33-fold)
from the reporter 5UGal4WE1BWCAT (Fig. 6A, compare lane 4
to lane 1). Co-transfection of the expression vector driving
synthesis of only the GAL4 DNA binding domain did not
show activation (Fig. 6A, lane 1). Co-transfection of v-Src,
but not c-Src, with GAL4-EWS(NTD) enhanced the response
of the 5UGAL4WE1bWCAT reporter up to 107-fold in a dose-
dependent fashion (Fig. 6A, compare lanes 5 and 6 to lane 4).
This enhancement by v-Src was EWS(NTD)-dependent since
v-Src had no e¡ect on the transcription response mediated by
GAL4 (Fig. 6A, compare lanes 2 and 3 to lane 1).
To further explore the e¡ect of v-Src on EWS-NTD medi-
ated transcription, three v-Src mutants (v-Src vSH3WSH2,
lacking SH3 and SH2 domains; v-Src vKinase, a kinase do-
main deletion mutant; and v-Src R295K, a kinase negative
mutant harboring a lysine to arginine missense mutation in
the kinase domain) were introduced in the transfection assay
described above (Fig. 6B). All three mutants failed to stimu-
late transcription by EWS/WT1, suggesting a requirement for
Fig. 5. Tyrosine phosphorylation of EWS/WT1 by Src. A: In vitro
phosphorylation of EWS/WT1 by Src tyrosine kinase. Two micro-
grams of GST or GST-EWS/WT1 were incubated with commercially
available Src (Oncogene Research Products, MA, USA) with 50 WM
ATP and 10 WCi of [Q-32P]ATP (3000 Ci/mmol) in a reaction mix-
ture for 20 min at 30‡C. For each reaction, 1 Wg of MBP was used
as an internal control to monitor Src kinase activity. Reaction mix-
tures were resolved on a 15% SDS^PAGE and labeled proteins were
visualized by exposing the dried gel to X-ray ¢lm (Kodak). The
presence of Src, myelin basic protein (MBP), GST, or GST-EWS/
WT1 in each incubation is indicated above the lanes. B: Phospho-
amino acid analysis of phosphorylated EWS/WT1 protein by Src in
vitro. Acid hydrolysates of phosphorylated GST-EWS/WT1 were
prepared and fractionated by electrophoresis on thin layer cellulose
at pH 1.9 (¢rst dimension) and pH 3.5 (second dimension). The po-
sitions of unlabeled standards, detected with ninhydrin, are shown
as pS (phosphoserine), pT (phosphothreonine), and pY (phosphotyr-
osine). The autoradiograph shows 32P migrating with phosphotyro-
sine (pY), orthophosphate (Pi), and di-amino acids. C: Tyrosine
phosphorylation of EWS/WT1 by ectopically expressed v-Src in
vivo. Plasmid encoding (His)6-EWS/WT1, and either v-Src or the
empty vector (pcDNA3), were co-transfected into C33A cells. Re-
combinant (His)6-EWS/WT1 protein was pulled down by Ni-NTA
agarose. The presence of EWS/WT1 protein was con¢rmed with an
anti-WT1 zinc ¢nger antibody (C-19, Santa Cruz Biotechnology
Inc.) (top panel) and tyrosine phosphorylation was detected with an
anti-phosphotyrosine antibody (4G10) (bottom panel).
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a region encompassed by the SH3 and SH2 domains, and for
the kinase domain of v-Src, for this e¡ect (compare lanes 8^10
to lane 7).
4. Discussion
The results reported herein begin to explore the functional
regulation of the EWS/WT1 oncoprotein. The EWS/WT1 fu-
sion protein has been proposed to play an important role in
the development of DSRCT [3]. In support of this notion,
expression of EWS/WT1(3KTS) is oncogenic when intro-
duced into NIH3T3 cells [13]. One model to explain how
EWS/WT1 mediates transformation is that it binds to DNA
recognition elements normally regulated by WT1, or other
related zinc ¢nger proteins, and alters the transcriptional sta-
tus of these genes. One potential downstream candidate is
PDGF-A, since this gene: (i) is overexpressed in a stable cell
line expressing EWS/WT1(3KTS), (ii) is expressed in speci-
mens of DSRCT, and (iii) responds to EWS/WT1 in vitro
[10].
The modulation of EWS/WT1 activity by regulatory pro-
teins has not been extensively studied. We have previously
documented that EWS/WT1 is phosphorylated in vitro and
in vivo by the nuclear tyrosine kinase, c-Abl, and that this
inhibits EWS/WT1 DNA binding and self-association [26].
The results presented herein indicate that EWS/WT1 activity
can also be regulated by a signaling pathway under control of
(a) cytoplasmic kinase(s). A number of studies have shown
that the v-Src protein tyrosine kinase can deregulate gene
expression, such as fos and jun [32^36]. In addition, many
signalling molecules, such as v-Src, ras, and Btk, enhance
the transcriptional activity of several transcription factors,
such as AP-1 [37,38] or TFII-I [23]. Also, cells expressing
the v-Src oncogene have increased expression of HIF-1,
VEGF, and ENO1 under both hypoxic and non-hypoxic con-
ditions and this is associated with increased transcription [39].
Thus, in the current study, it is likely that v-Src activates a
signal transduction pathway that leads to the potentiation of
transcription activation by EWS/WT1 (Fig. 6).
SH2 and SH3 domains mediate a variety of physiological
responses and are found together on many proteins [40], sug-
gesting that their activities may be coordinated. Interestingly,
the NTD of EWS/WT1 (aa 70^163) contains three proline-
rich motifs which could provide binding sites for the v-Src
SH3 (Src homology 3) domain (Fig. 2). Our results indicate
that EWS/WT1 can interact with the SH2 domain of v-Src,
but we have not attempted to de¢ne the responsible EWS/
WT1 domain. The binding of EWS/WT1 to SH3 domains
does not appear to be promiscuous since, when presented
with nine possible SH3 domains, EWS/WT1 only bound to
three (Fig. 1).
The EWS protein can be phosphorylated by a number of
kinases. For example, protein kinase C phosphorylates EWS
through an IQ domain and inhibits its RNA binding activity
[41]. Since the EWS/WT1 chimeric protein does not retain the
IQ domain, it is not expected to be a substrate for protein
kinase C. In addition, EWS has been reported to associate
with, and be a substrate for, Bruton’s tyrosine kinase (BTK)
and the Pyk2 tyrosine kinase [42,43]. Both of these kinases are
cytoplasmic, and it is thought that extranuclear EWS is the
target of these enzymes. Analysis of the EWS/WT1 protein
sequence (performed at http://www.cbs.dtu.dk/services/Net
Phos/) revealed the presence of 13 potential tyrosine phos-
phorylation sites (indicated by underscores within the se-
quence: 2ASTDYSTYS10, 25PTQGYAQTT33, 40SYGTYG-
QPT48, 48TDVSYTQAQ56, 62GQTAYATSY70, 66YATSYG-
QPP74, 73PPTGYTTPT81, 154STGGYNQPS162, 161PSLGY-
GQSN169, 168SNYSYPQVP176, 191PPTSYSSTQ199, 199QPTS-
YDQSS207, and 204DQSSYSQQN212). Although our data
strongly suggest that EWS/WT1 is a substrate for v-Src in
vivo, it is not clear how the cytoplasmic membrane-integrated
v-Src modi¢es the nuclear localized EWS/WT1. It is possible
that extranuclear EWS/WT1 is a substrate for modi¢cation by
v-Src. Alternatively, and not mutually exclusive, is the possi-
bility that v-Src activates a pathway that leads to nuclear
modi¢cation of EWS/WT1.
Our results also demonstrate that v-Src has a striking e¡ect
on the activation properties of the EWS-NTD (Fig. 6). Also,
deletions of v-Src a¡ecting a domain encompassed by the SH3
and SH2 regions, or by the kinase domain, abolished stimu-
lation of EWS/WT1 activation (Fig. 6B) suggesting the re-
quirement of these regions for v-Src activity in this assay. It
is currently unclear to us why c-Src did not potentiate the
EWS-NTD transcriptional properties (Fig. 6A). A compara-
tive study between c-Src and v-Src has revealed that v-Src has
three point mutations in its SH3 domain and one upstream of
SH3, and that engineering these mutations into c-Src con-
verted c-Src to be oncogenic and active in kinase activity
[44]. In addition, three-dimensional structural analysis of c-
Src has shown that interaction among domains, stabilized
by binding of the phosphorylated tail to the SH2 domain,
locks the molecule in a conformation that simultaneously dis-
rupts the kinase active site and sequesters the binding surfaces
of the SH2 and SH3 domains. Mutations in v-Src are pre-
dicted to break these interactions, producing an open active
kinase [45]. Thus it is clear that these two proteins di¡er in
enzymatic and functional properties.
It will be important to assess the phosphorylation status of
EWS/WT1 in DSCRTs since this event could provide insight
into the activity of EWS/WT1 in this malignancy. If signaling
pathways involved in modifying EWS/WT1 function are
usurped in this malignancy, then de¢ning these events be-
comes important for understanding progression in this malig-
nancy.
Fig. 6. Functional in£uence of v-Src on the transcription activity of
EWS(NTD). A: Stimulation of EWS mediated transactivation by v-
Src. Two micrograms of GAL4 or GAL4-EWS(NTD) plasmids
were co-transfected with 0, 1, or 5 Wg of v-Src (black bar) or c-Src
(hatched bar) expressing plasmid into C33A cells. CAT activity was
measured after normalization to L-galactosidase activity and ex-
pressed as fold activation relative to the basal level observed with
the 5UGAL4WE1bWCAT reporter plasmid and the GAL4 DNA bind-
ing domain alone (lane 1). The average of two independent experi-
ments is presented. B: v-Src SH3 and SH2 domains as well as ki-
nase domain are required for the enhancement of EWS(NTD)
mediated transactivation. Two micrograms of GAL4 or GAL4-
EWS(NTD) expression plasmids were co-transfected with 5 Wg of
v-Src or v-Src mutants (v-Src vSH3WSH2 (SH3 and SH2 domain de-
letion mutant), v-Src vKinase (kinase domain deletion), and v-Src
R295 (kinase inactivation mutant with lysine to arginine mutation
in kinase domain)) into C33A cell line, respectively. CAT activity
was measured after normalization to L-galactosidase activity and ex-
pressed as fold activation relative to the basal level observed with
the 5UGAL4WE1bWCAT reporter plasmid and the GAL4 DNA bind-
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